Today, we want to point out a new publication that dives into the world of senolytics, which are drugs or therapies that seek and destroy harmful non-dividing cells that resist the programmed cell death known as apoptosis. These cells linger in the body, and, as we age, more and more of them accumulate and contribute…

Citi has produced another of its Disruptive Innovations publications, which takes a look at what it considers to be the top ten disruptive technologies. It is a sign of the changing times that anti-aging medicines are number 2 in its list. 1. All-Solid-State Batteries 2. Anti-Aging Medicines 3. Autonomous Vehicle Networks 4. Big Data &…

Today, we wanted to draw your attention to a recent study showing an association between the accumulation of Tau proteins, which are misfolded proteins that typically indicate Alzheimer’s disease and senescent cells. The researchers also showed that Tau pathology was improved by the use of drugs that remove non-dividing senescent cells. Unfortunately, this journal paper…

Today, we would like to share with you the talk given by Kelsey Moody, CEO of Biotech Company Ichor, at the recent Ending Age-Related Diseases: Investment Prospects & Advances in Research conference in New York City. In this talk, Kelsey discusses Ichor’s protein engineering platform, how Ichor has used it, and Ichor’s plans for using it to…

We have interviewed Dr. Peter de Keizer, a researcher who is engaged in studying senescent cells and designing therapies to destroy them in order to delay and prevent age-related diseases. Cleara Biotech is currently using his research to develop a senolytic peptide that accomplishes this via interfering with the interactions between p53 and FOXO4. Senescent…

We wanted to draw your attention to a new publication by James Kirkland and his team. Kirkland is one of the pioneers of senolytics, as he demonstrated that a combination of compounds could remove senescent cells and improve healthspan in mice back in 2015 [1]. The contribution of senescent cells to aging has been the…

Interest in therapies that remove senescent cells from the body, known as senolytics, has grown massively in the last year or so. There are now a number of companies actively developing senolytic therapies, including UNITY Biotechnology, Oisin Therapeutics, and Antoxerene. Recently, another company, Cleara Biotech, has arrived on the scene. We anticipated this last year…

Senolytics have been in the news a great deal ever since van Deursen and his team conducted a landmark 2011 study showing that removing senescent cells could delay age-related ill health in mice [1]. Since then, interest in what was once a niche topic has continued to grow at an ever-increasing pace. Now, there are…

July is here, and our upcoming conference in New York City is only a handful of days away! If you haven’t done so already, go and get your ticket now so that you can enjoy the June roundup fully relaxed, knowing that your seat is secured. About our NYC conference On the off chance you’ve…

Today we are pleased to announce that UNITY Biotechnology is going into human clinical trials with the first true rejuvenation therapy that directly targets one of the processes of aging: senescent cells. The quiet revolution In our collective imagination, revolutions start with a bang; however, more often than not, real-life technological revolutions start quietly and…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD